Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
Part of paid clinical trials in New York, New York.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT00003427
- Phase
- PHASE1
- Status
- Completed
Conditions
- Anal Cancer
- Colorectal Cancer
- Esophageal Cancer
- Extrahepatic Bile Duct Cancer
- Gallbladder Cancer
- Gastric Cancer
- Gastrointestinal Carcinoid Tumor
- Liver Cancer
- Pancreatic Cancer
- Small Intestine Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- irinotecan hydrochloride — DRUG
- oxaliplatin — DRUG
Study Details
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of oxaliplatin plus irinotecan in treating patients with previously treated metastatic gastrointestinal cancer that has not responded to previous treatment.
Key Dates
- Start date
- Apr 30, 1998
- Status verified
- Jun 2013
- Primary completion
- Apr 30, 2002
- Completion
- Apr 30, 2002
Study Design
- Enrollment
- 36 participants (estimated)
- Primary purpose
- TREATMENT
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | - |
Find similar trials in New York, NY
By specialty
By research site
Related Studies
- PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic DiseaseRecruiting · Columbia University · New York, New York
- Pancreatic Cancer GeneticsRecruiting · Columbia University · New York, New York
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic CancerRecruiting · Memorial Sloan Kettering Cancer Center · New York, New York